Search

VIPEACE is the house of exclusivity in Adam's Morgan. Our unique clothing items and our fine selection of cannabis is the best in Washington DC. We provide an exclusive experience and are conveniently located. Everyone who comes in Peace is very important to us. We welcome you to experience the finest that DC has to offer. VIPeace WEBSITE MENU REVIEWS 2118 18th St, Basement NW Washington, DC 20009 (202) 525-1348 VIPEACE is the house of exclusivity in Adam's Morgan. Our unique clothing items and our fine selection of cannabis is the best in Washington DC. We provide an exclusive experience and are conveniently located. Everyone who comes in Peace is very important to us. We welcome you to experience the finest that DC has to offer. Hours: Open 12 - 8 PM Daily Peace In The Air Recent Reviews Cutiez - VIPeace Dark, frosty, and formidably potent this batch of Cutiez courtesy of DC i-71 marijuana dispensary, VIPeace, turns heads for all the right... Terp Interpreter Oct 10, 2023 1 min read True Chocolate - VIPeace With an aroma that's actually a lot like chocolate this True Chocolate from DC i-71 marijuana dispensary, VIPeace, is certainly one to co... Elle Weeds Sep 28, 2023 1 min read Gumbo Runtz - VIPeace Check out this batch of Gumbo Runtz from DC i-71 marijuana dispensary, VIPeace. These buds are exotically enchanting and remind me of a t... Terp Interpreter Aug 29, 2023 1 min read Coco Chanel - VIPeace This Coco Chanel, from DC i-71 marijuana dispensary, VIPeace, is named as a playful nod to the iconic French fashion designer Gabrielle "... Terp Interpreter Aug 16, 2023 1 min read Lemon Tree - VIPeace With heavy trichomes and a citrus tinged aroma this batch of Lemon Tree from DC i-71 cannabis dispensary, VIPeace, is one to consider pic... Elle Weeds Jul 28, 2023 1 min read Cookies and Cream - VIPeace Originally bred by Exotic Genetix, the Cookies and Cream strain is a sweet-tasting cultivar that took first place in the hybrid category... Toker's Guide Jun 9, 2023 1 min read Glitter Box - VIPeace Glitter Box is a creation originally out of Fuego Family Farms that's currently available from DC i-71 storefront dispensary, VIPeace. As... Toker's Guide May 12, 2023 2 min read

A study on elite Canadian athletes found that 38% use CBD for recovery, pain relief, and improved sleep, but many worry about inadvertent anti-doping violations because trace amounts of prohibited cannabinoids like THC are often present in commercial CBD products, creating a "fine line" for competitors. < Back CBD Provides Pain Relief, Improves Sleep And Aids Relaxation, Study Involving Olympic Athletes Shows Dec 16, 2025 Aaron Houston Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Elite athletes find cannabidiol, or CBD, useful for soreness and recovery, a new study shows. Researchers found that top competitors use CBD to manage pain, improve sleep and ease the stress of training at the highest level. But the results suggest that even as many athletes believe the cannabis compound helps them recover, they also worry that using it could jeopardize their careers under international anti-doping rules. The study, conducted between late 2021 and mid-2023 and published this month in the journal Frontiers in Nutrition, surveyed 80 elite Canadian athletes across 27 national sport organizations. To be included, athletes needed to have experience as part of the country’s Olympic or Paralympic team program. About 38 percent reported using CBD at some point, and nearly a third of those said they were still using it at the time of the survey. The participants’ motivations reflect a broader societal trend of relying on CBD for therapeutic benefit. The study found that 96 percent of CBD users said they believed the substance was safe, 93 percent said it improved their sleep, 90 percent said it helped them relax and 77 percent credited it with reducing pain from training. “Thirty eight percent of athletes self-reported using CBD, and cumulatively agreed or strongly agreed that CBD improved sleep and relaxation, reduced pain from training, and enhanced physical and mental recovery following training or competition.” Despite the reported benefits, CBD use among athletes remains a controversial topic. Although the World Anti-Doping Agency removed CBD from its list of banned substances in 2018, all other cannabinoids—including THC—remain prohibited. This creates conditions the authors describe as “a fine line between unintentional doping and intentional use of cannabis products.” Because many commercially available CBD products contain trace levels of these banned compounds, athletes who rely on them may be risking inadvertent doping violations. That concern, researchers found, was the single most common reason athletes chose not to try CBD or stopped using it altogether. The authors, affiliated with McGill University and the Canadian Sport Institute, also noted that “some CBD-fortified foods and beverages have been reported to convert CBD into THC under low pH conditions…potentially yielding sufficient THC (3 mg) to trigger a positive urine test for prohibited cannabinoids.” They further observed that physical exertion prior to testing may increase detectable THC levels. Altogether, the situation puts athletes in a kind of limbo. Those who feel genuine relief from CBD are left to navigate a market where product labels can’t always be trusted and scientific guidance remains sparse. Many said they first heard about CBD through friends or online, not from sports physicians or trainers. “Many athletes expressed concerns about the potential for inadvertent anti-doping rule violations due to CBD product contamination with THC or other banned cannabinoids.” “Given that athletes frequently reported obtaining information on CBD from friends and online sources,” the authors wrote, “there is also a need to test interventions that enhance evidence-based knowledge among both athletes and clinicians.” The study comes following sports leagues in the U.S. taking steps to update their marijuana policies as legalization becomes more widespread, including the National Collegiate Athletic Association (NCAA) and the National Football League (NFL). An NFL-funded study from 2024 found that marijuana use is becoming more widely accepted among athletes. The authors of that paper noted that “education and awareness on benefits and potential harm is needed for athletes, medical staff, and policymakers.” Meanwhile, the Major League Baseball (MLB) removed marijuana from its list of banned substances in 2019. The National Basketball Association followed suit in 2023. The post CBD Provides Pain Relief, Improves Sleep And Aids Relaxation, Study Involving Olympic Athletes Shows appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The infused line extension, blending bold flavor with American tradition, is now available at Curaleaf stores in Arizona, Illinois, New Jersey, and New York. < Back Curaleaf Launches Anthem Bold Infused Pre-Rolls in 4 States Sep 29, 2025 Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The infused line extension pairs bold flavor with American tradition, now available at Curaleaf stores in Arizona, Illinois, New Jersey and New York. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The DEA administrative law judge overseeing the marijuana rescheduling process, John Mulrooney, is retiring, leaving the case to the newly confirmed DEA administrator, Terrance Cole... < Back DEA Judge Overseeing Marijuana Rescheduling Retires, Leaving Fate Of Reform To Trump’s New Agency Head Jul 23, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Drug Enforcement Administration (DEA) judge who’s overseen the ongoing marijuana rescheduling process is retiring, saying that “all matters filed in this case will be forwarded to” President Donald Trump’s newly Senate-confirmed agency administrator “for whatever action, if any, he deems appropriate,” as there is for now no judge to hear the issue. Just one day after the Senate confirmed Terrance Cole as the new head of DEA, Administrative Law Judge (ALJ) John Mulrooney notified witnesses in the cannabis rescheduling proceedings that, effective August 1, “I will be retired from the bench.” “My retirement will leave the DEA with no Administrative Law Judge to hear this matter or any of the Agency’s other pending administrative enforcement cases,” Mulrooney said. “The Controlled Substances Act requires that DEA administrative enforcement hearing proceedings must be conducted in accordance with the Administrative Procedure Act and presided over by an Administrative Law Judge. 21 U.S.C. § 824(c)(4); 5 U.S.C. § 556(b)(3),” he said. “Until there is a change in this circumstance, all matters filed in this case will be forwarded to the DEA Administrator, for whatever action, if any, he deems appropriate.” “All previously-issued procedural orders remain in full force and effect unless otherwise modified by a successor Administrative Law Judge, the DEA Administrator, or the Attorney General. Naturally, I wish all the parties the best in resolving this important issue in a fair, transparent, and accurate manner, and extend my heartfelt gratitude to the parties and their representatives for their sincere, diligent, and indefatigable advocacy.” What this means is that, for the time being at least, the stalled-out rescheduling case will be squarely within the purview of Cole, the newly confirmed administrator of DEA. Notably, while Cole has said that examining the rescheduling proposal would be “one of my first priorities” if he was confirmed for the role, he has refused to say what he wants the result to be and has in the past made comments expressing concerns about the health effects of cannabis. In May, a Senate committee advanced the nomination of Cole to become DEA administrator amid the ongoing review of the marijuana rescheduling proposal that he has so far refused to commit to enacting. Cole—who has previously voiced concerns about the dangers of marijuana and linked its use to higher suicide risk among youth—said in response to senators’ written questions that he would “give the matter careful consideration after consulting with appropriate personnel within the Drug Enforcement Administration, familiarizing myself with the current status of the regulatory process, and reviewing all relevant information.” Meanwhile, earlier this month, DEA again notified Mulrooney that the marijuana rescheduling process remains stalled under the Trump administration. It’s been six months since Mulrooney temporarily paused hearings on a proposal to move cannabis from Schedule I to Schedule III of the CSA that was initiated under the Biden administration. And in a joint report to the judge submitted on Monday, DEA attorneys and rescheduling proponents said they’re still at an impasse. The judge initially agreed to delay the rescheduling proceedings after several pro-reform parties requested a leave to file an interlocutory appeal amid allegations that certain DEA officials conspired with anti-rescheduling witnesses who were selected for the hearing. Originally, hearings on the proposed rescheduling rule were set to commence on January 21, but those were cancelled when Mulrooney granted the appeal motion. The appeal came after the judge denied a motion that sought DEA’s removal from the rescheduling proceedings altogether, arguing that it is improperly designated as the chief “proponent” of the proposed rule given the allegations of ex parte communications with anti-rescheduling witnesses that “resulted in an irrevocable taint” to the process. Meanwhile, the Justice Department told a federal court in January that it should pause a lawsuit challenging DEA’s marijuana rescheduling process after Mulrooney canceled the hearings. Also in January, Mulrooney condemned DEA over its “unprecedented and astonishing” defiance of a key directive related to evidence it is seeking to use in the marijuana rescheduling proposal. At issue was DEA’s insistence on digitally submitting tens of thousands of public comments it received in response to the proposed rule to move cannabis to Schedule III. Mulrooney hasn’t been shy about calling out DEA over various procedural missteps throughout this rescheduling process. For example, in December he criticized the agency for making a critical “blunder” in its effort to issue subpoenas to force Food and Drug Administration (FDA) officials to testify in hearings—but he allowed the agency to fix the error and ultimately granted the request. Relatedly, a federal judge also dismissed a lawsuit seeking to compel DEA to turn over its communications with the anti-cannabis organization. Mulrooney had separately denied a cannabis research company’s request to allow it to add a young medical marijuana patient and advocate as a witness in the upcoming rescheduling hearing. Also, one of the nation’s leading marijuana industry associations asked the judge to clarify whether it will be afforded the opportunity to cross-examine DEA during the upcoming hearings on the cannabis rescheduling proposal. Further, a coalition of health professionals that advocates for cannabis reform recently asked that the DEA judge halt future marijuana rescheduling hearings until a federal court is able to address a series of allegations they’re raising about the agency’s witness selection process. Separately, the House Appropriations Committee on Tuesday approved a spending bill that contains provisions to block the Justice Department from rescheduling marijuana. The rescheduling proceedings have generated significant public interest. While moving marijuana to Schedule III wouldn’t federally legalize it, the reform would free up licensed cannabis businesses to take federal tax deductions and remove certain research barriers. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Meanwhile, two GOP senators introduced a bill in February that would continue to block marijuana businesses from taking federal tax deductions under Internal Revenue Service (IRS) code 280E—even if it’s ultimately rescheduled. Beyond the hearing delays, another complicating factor is the change in leadership at DEA under the Trump administration. U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. was previously vocal about his support for legalizing cannabis, as well as psychedelics therapy. But during his Senate confirmation process in February, he said that he would defer to DEA on marijuana rescheduling in his new role. Separately, former Rep. Matt Gaetz (R-FL) was reportedly photographed reviewing a document that appears to be a draft contract to provide services—including “administration-related guidance”—to a firm affiliated with the major marijuana company Trulieve. The visible portion of the document describes a lucrative bonus if a certain “matter resolves,” with an “additional ‘Super Success Fee’” for other “exclusive policy remedies.” Last month, the former congressman reiterated his own support for rescheduling cannabis—suggesting in an interview with a Florida Republican lawmaker that the GOP could win more of the youth vote by embracing marijuana reform. Gaetz also said last month that Trump’s endorsement of a Schedule III reclassification was essentially an attempt to shore up support among young voters rather than a sincere reflection of his personal views about cannabis. A survey conducted by a GOP pollster affiliated with Trump that was released in April found that a majority of Republicans back a variety of cannabis reforms, including rescheduling. And, notably, they’re even more supportive of allowing states to legalize marijuana without federal interference compared to the average voter. Meanwhile, Trump picked former Florida Attorney General Pam Bondi (R) to run DOJ, and the Senate confirmed that choice. During her confirmation hearings, Bondi declined to say how she planned to navigate key marijuana policy issues. And as state attorney general, she opposed efforts to legalize medical cannabis. Amid the stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers recently reiterated that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges. Meanwhile, a newly formed coalition of professional athletes and entertainers, led by retired boxer Mike Tyson, sent a letter to Trump on Friday—thanking him for past clemency actions while emphasizing the opportunity he has to best former President Joe Biden by rescheduling marijuana, expanding pardons and freeing up banking services for licensed cannabis businesses. *Read the letter from the DEA judge to marijuana rescheduling witnesses below: * *Photo elements courtesy of rawpixel and Philip Steffan.* The post DEA Judge Overseeing Marijuana Rescheduling Retires, Leaving Fate Of Reform To Trump’s New Agency Head appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Green Flash Delivery is redefining convenience, quality & community in the Boston weed scene. Learn more about this Roxbury-born brand. The post Green Flash: Delivering Boston’s cannabis future appeared first on Leafly. < Back Green Flash: Delivering Boston’s cannabis future Apr 30, 2025 Leafly Staff Leafly Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Green Flash Delivery is redefining convenience, quality & community in the Boston weed scene. Learn more about this Roxbury-born brand. The post Green Flash: Delivering Boston’s cannabis future appeared first on Leafly. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

< Back GMO Cookies (Indica) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) 4.7 142 Ratings average rating is 4.7 out of 5, based on 142 votes, Ratings $40.00 3.5g Order Now Description GMO Cookies is a premium Grade A indica strain with 20.3% THC, known for its garlicky aroma. It offers relaxation, sleepiness, and a body buzz, ideal for unwinding or pain relief. Effects relaxed, sleepy, tingly Previous Next Cheetah Piss (Sativa) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) $40.00 Order 4.8 172 Ratings average rating is 4.8 out of 5, based on 172 votes, Ratings Lemon Haze (Sativa) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) $40.00 Order 4.8 169 Ratings average rating is 4.8 out of 5, based on 169 votes, Ratings Forum Cookie (Indica) by Premium Cultivars - THCA Flower | Premium Indoor 8th (3.5g) $40.00 Order 4.8 168 Ratings average rating is 4.8 out of 5, based on 168 votes, Ratings

*SC gov: medical marijuana “compelling”; TX gov signs psychedelics bill; FL medical cannabis patient penalty; OH legalization amendments limited*. Members of the Mississippi Band of Choctaw Indians approved a cannabis referendum. Texas Gov. Greg Abbott signed a bill to create an ibogaine therapy research consortium. South Carolina Gov. Henry McMaster said the case for legalizing medical cannabis is “very compelling.” A Florida legislative committee is poised to approve a bill to revoke medical cannabis patient and caregiver registrations. Ohio’s Constitution allows lawmakers to enact only limited changes to the marijuana legalization law. A poll found that a majority of Texas Republican primary voters believe that legislation to ban consumable hemp products with any amount of THC will “create opportunities for drug cartels”. < Back Indian tribe passes cannabis legalization referendum (Newsletter: June 12, 2025) Jun 12, 2025 Tom Angell Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *SC gov: medical marijuana “compelling”; TX gov signs psychedelics bill; FL medical cannabis patient penalty; OH legalization amendments limited* Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: *Your support makes Marijuana Moment possible…* *Free to read (but not free to produce)!* We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment */ TOP THINGS TO KNOW* Members of the Mississippi Band of Choctaw Indians approved a cannabis referendum that supports the tribe “developing legislation to decriminalize and regulate the possession, production, and distribution of marijuana.” Texas Gov. Greg Abbott (R) signed a bill to create an ibogaine therapy research consortium, through which the state would retain a commercial interest in “all intellectual property…generated over the course of the drug development clinical trials” on the psychedelic. South Carolina Gov. Henry McMaster (R) said the case for legalizing medical cannabis is “very compelling” despite law enforcement’s concerns, while a key senator says 2026 should be the year to finally enact the reform. A Florida legislative conference committee is poised to approve a bill to revoke medical cannabis patient and caregiver registrations from anyone convicted of certain drug crimes, including simply purchasing more than 10 grams of marijuana. Ohio’s Constitution allows lawmakers to enact only limited changes to the marijuana legalization law approved by voters, according to an analysis by Derek Clinger of the University of Wisconsin Law School’s State Democracy Research Initiative. A poll found that a majority of Texas Republican primary voters believe that legislation to ban consumable hemp products with any amount of THC that’s on Gov. Greg Abbott’s (R) desk will “create opportunities for drug cartels” and “increase black market sales”—with 72 percent saying that “military veterans should be able to access THC products as an alternative to opioids.” Texas Lt. Gov. Dan Patrick (R) is seeing a rare backlash from the political right over his push to ban all consumable hemp products with any amount of THC. Montana Gov. Greg Gianforte (R) vetoed a bill to allocate marijuana revenue to a variety of conservation, law enforcement, addiction treatment and homelessness support initiatives. The Massachusetts House of Representatives passed a bill to allow intoxicating hemp-derived drinks to be sold in liquor stores while taking edibles like THC gummies off store shelves, but the head of the Cannabis Control Commission says lawmakers aren’t providing adequate funding for enforcement. */ FEDERAL* Former White House Office of National Drug Control Policy Deputy Director for Demand Reduction Bertha Madras coauthored an article criticizing the Department of Health and Human Services’s marijuana rescheduling recommendation. Rep. Dina Titus (D-NV) tweeted about President Donald Trump’s budget request to delete state medical cannabis protections, saying, “It’s time to puff, puff, pass the bill and not listen to @POTUS. He is trying to reverse our progress in smart cannabis reform.” */ STATES* Oregon Gov. Tina Kotek (D) signed bills amending various cannabis and hemp rules. Texas Gov. Greg Abbott (R) said he still hasn’t decided whether to sign a bill to ban consumable hemp products with any amount of THC. The Washington, D.C. Council is considering legislation to create a new “craft preparation endorsement” allowing medical cannabis dispensaries to prepare certain products on site. New York regulators announced a recall of marijuana products due to the presence of unallowable pesticides. Minnesota regulators mistakenly told winners of a marijuana business license lottery that they were not selected. Separately, a State Patrol official spoke about efforts to detect marijuana-impaired driving. Louisiana regulators filed changes to medical cannabis rules. Colorado regulators published guidance on psychedelic transfer and transportation rules. The Massachusetts Cannabis Control Commission released the final version of its new governance charter. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* */ LOCAL* Denver, Colorado officials clarified that there is no longer a requirement that certain marijuana business license applications undergo a public hearing under newly enacted legislation. */ INTERNATIONAL* Bayreuth, Germany officials dropped proceedings against a person who was accused of failing to protect their home marijuana cultivation operation from access by third parties. */ SCIENCE & HEALTH* A case study found that “regular, 3-month application of the emulsion based on Cannabis Sativa L. oil considerably reduced inflammation, erythema, pruritus, xerosis and scaling of the skin, soothing excoriations and lichenification.” A study of mice “observed a beneficial effect of CBD in motor and neuronal alterations reserpine-induced progressive parkinsonism, particularly after preventive treatment.” */ ADVOCACY, OPINION & ANALYSIS* The Pennsylvania Family Institute’s chief strategy officer authored an op-ed urging Pennsylvania lawmakers not to legalize marijuana. */ BUSINESS* 4Front Ventures Corp. initiated Bankruptcy and Insolvency Act proceedings in Canada. Tilray Brands, Inc. shareholders approved a reverse stock split. NuggMD announced that it now provides access to medical cannabis evaluations in every state where telemedicine is allowed for such recommendations. Missouri retailers sold $132.8 million worth of legal marijuana products in May. *Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.* Get our daily newsletter. Email address: Leave this field empty if you're human: *Photo courtesy of Chris Wallis // Side Pocket Images.* The post Indian tribe passes cannabis legalization referendum (Newsletter: June 12, 2025) appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

- The cannabis market is shifting from recreational use to wellness, with 64 percent of consumers citing relaxation as their primary motivation. - The new consumer is more informed, female, digitally savvy, and prefers discreet formats like edibles and infused beverages over flower. - To thrive in 2026, brands must overhaul their strategy to lead with wellness positioning, invest heavily in personalization and data, embrace science-backed education, and optimize for digital-first discovery and shopping. < Back 2026 Cannabis Marketing Playbook: Consumer Shifts You Can’t Ignore Dec 17, 2025 Sue Dehnam MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Let’s be honest: *If you haven’t rebuilt your 2026 marketing plan from scratch, it’s already out of date.* The cannabis consumer has changed dramatically — even compared to last year. They’re shopping like they buy skincare, not flower. They expect personalized recommendations, trust founder-led brands, and gravitate toward discreet formats like edibles and THC beverages. This isn’t a tweak-your-messaging moment. It’s a full strategy reset. Here’s what the new consumer wants — and how brands can meet them where they actually live. *It all starts with the biggest shift driving the entire market:* the rise of cannabis as a wellness staple rather than a recreational escape. Wellness is redefining the cannabis consumer The stereotype of cannabis as a party drug is officially dead. Today’s consumers are reaching for cannabis products the way they once reached for melatonin, ibuprofen, or a glass of wine after a stressful day. Sixty-four percent of consumers cite relaxation as their primary motivation, according to Brightfield Group, while 30 percent now prefer cannabis over alcohol entirely. *64 percent of consumers* now say relaxation — not intoxication — is their primary reason for using cannabis, underscoring the category’s shift toward wellness-driven demand. “Consumers are leaning into cannabis for wellness,” said Anne Donohoe, managing director at KCSA Strategic Communications. “Sleep, stress, and pain-management are top drivers. Interest in minor cannabinoids like CBN, CBG, and THCV is growing.” The data bears this out: One-fifth of Dry January participants this year swapped alcohol for THC or CBD products, with Gen Z and millennials leading the charge. One in three people in those age demographics now regularly choose THC beverages at happy hours. In Canada, 70 percent of adults support federal investment in cannabis wellness research. For marketers, this shift demands a complete messaging overhaul. “The rise of microdosing, edibles, and tinctures for specific uses means marketers should position products not just for recreation, but as a tool for achieving a specific outcome,” advised Dan Serard, senior vice president at Cannabis Creative Group. Demographics have shifted — and so must your messaging If your target demographic is still young men, you’re marketing to yesterday’s consumer. Women now compose more than half of cannabis users, according to Headset, and they skew toward wellness products, with 29 percent preferring non-flower formats like topicals and edibles. Women now account for *more than half of cannabis consumers*, while millennials and Gen Z together drive *63 percent of total U.S. cannabis spending*. Millennials capture 46 percent of U.S. spending, while Gen Z and millennials together drive 63 percent of total sales. Middle-aged adults (35–54) increasingly identify as cannabis consumers as legalization and normalization reduce stigma. Among younger demographics, 59 percent of female consumers under age 35 report planning to increase their use of canna bis products. “Cannabis is no longer the new kid on the block, and that means consumers are more intelligent than when the market first opened up,” Serard said. “They’re informed and have specific demands related to their individual goals. Companies should be paying attention to these new personas and tailoring their messaging accordingly.” Science-backed buying is the new baseline The days of marketing based solely on THC percentage are over. Today’s educated consumers seek products engineered for specific effects rather than just maximum potency; consequently, they want to understand the full cannabinoid and terpene profile. *Four in ten consumers* now use CBD products, reflecting growing interest in cannabinoids, terpene profiles, and outcome-based shopping. “Consumers are past focusing solely on THC percentage,” Serard said. “They are increasingly interested in the minor cannabinoids, terpenes, and the effects they produce. Marketing needs to be more educational, detailed, and science-backed.” This sophistication extends to sourcing and quality. According to Nielsen IQ, 40 percent of consumers opt for CBD variants, and demand is spiking for premium, terpene-rich buds from living soil versus synthetic growing methods. Consumers are rejecting mediocre products in favor of flavorful, residue-free options that emphasize sustainability and organic sourcing. Formats are diversifying faster than brands can adapt A Statista analysis revealed that while 21 percent of consumers still prefer flower, the market is fracturing across categories. Edibles claim 16 percent of consumer preference, vapes and cartridges 15 percent, and pre-rolls 13 percent. Pre-roll sales jumped 12 percent this year to reach $4.1 billion, and beverages surged 11 percent to $54 million. Flower represents just *21 percent of stated consumer preference*, as edibles, vapes, pre-rolls, and beverages continue to gain share. “Product preferences are shifting from smoking toward gummies, beverages, and other discreet formats,” Donohoe observed. The convenience and discretion of these formats align perfectly with wellness-focused consumption patterns. Infused beverages represent a particularly interesting opportunity, with mainstream retailers like Target now test-marketing hemp-derived THC drinks in select Minnesota stores — a significant signal of growing mainstream acceptance. As normalization continues, expect the lines between cannabis and conventional wellness products to blur further. Digital-first shopping is now the default [image: A modern cannabis dispensary interior featuring large digital menu screens and interactive displays, reflecting the digital-first retail experience shaping cannabis shopping in 2026.]Digital menus and information-rich displays reflect how cannabis retail has evolved to meet consumer expectations shaped by e-commerce and on-demand shopping. (Photo: Cova Software) Today’s cannabis consumer shops like they’re buying groceries on Amazon, not visiting a specialty store. Seventy-nine percent of Americans now live near dispensaries, but proximity isn’t enough. Sixty-eight percent demand clear online menus, 67 percent expect delivery options, and 75 percent want one-click reordering capabilities, according to a Sweed survey. *68 percent of consumers* expect clear online menus before visiting a dispensary, and 75 percent say easy reordering influences where they shop. “Consumers are shopping digitally,” confirmed Eric Meth, chief innovation officer at Surfside. “The purchase journey now often begins online, even when the transaction ends in-store. In some markets, up to 60 percent of cannabis purchases are happening through e-commerce channels.” The payoff for getting this right is substantial: According to Flowhub, dispensaries offering debit payment see 59 percent more transactions and generate $4,600 more in daily revenue compared to cash-only operations. Loyalty programs retain 69 percent of users, while word-of-mouth and local search-engine optimization drive 41 percent of new customer discovery. But convenience alone isn’t enough. Half of consumers feel overwhelmed by product choices, and 57 percent won’t return to a dispensary or website if they experience inconsistent recommendations. This is where personalization becomes critical. Personalization is no longer optional [image: A cannabis retail associate assists a customer using a digital menu, reflecting how personalized guidance has become a core part of the modern dispensary experience.]Personalized guidance — powered by digital menus and delivered by people — is now a baseline expectation for cannabis shoppers, not a premium feature. (Photo: Cova Software) Generic marketing no longer moves the needle. Nearly nine in ten consumers return to brands that offer tailored recommendations, while surveys suggest more than half of digital-native Gen Z expect dynamic, behavior-based offers. Yet only 29 percent across the board feel they currently receive either experience. Nearly *nine in ten consumers* say they’re more likely to return to brands that offer personalized recommendations — yet only 29 percent feel they currently receive them. “Every dispensary serves a specific consumer base, whether it is neighborhood regulars or tourists,” said Shawna Seldon McGregor, founder of Maverick Public Relations. “Understanding what drives people to a store and why they purchase certain products is crucial. This is where PR comes in: How are you tracking and responding to that data?” The stakes are high: One-third of customer churn can be traced to irrelevant outreach. Customers who feel “seen” are more likely to reward brands and retailers with loyalty. Operators who deploy artificial-intelligence-powered recommendation engines and mood-based product matching can reduce the friction. Nearly two-thirds of consumers cite post-purchase education as a key influence on loyalty, offering another opportunity for personalized, value-added engagement. “Consumers expect brands to reflect their values, from sustainability to social impact, and they reward transparency,” McGregor said. Authenticity and founder-led storytelling win attention In an increasingly commoditized market, consumers are seeking genuine connections with the brands they support. This trend cuts against the consolidation happening among the top five brand houses, which now control 14 percent more market share than previously. “Founder-led brands, both business-to-business and business-to-consumer, are more powerful now than ever before,” said Michael Mejer, founder and chief executive officer at Greenlane Communication. “People don’t want to buy from a company; they want to know who they’re buying from and buying into with their hard-earned money.” This extends to how brands show up in consumers’ feeds and social channels. Micro-influencers and niche social platforms are capturing attention with organic content, while experiential marketing — virtual-reality strain tours, pop-up festivals, cannabis lounges — builds loyalty and normalizes use in social settings. “Experience-based consumption, such as lounges, is gaining traction,” Donohoe said, “signaling that consumers are looking for cannabis to fit into lifestyle and social settings.” Attention is splintering across platforms Traditional marketing playbooks are struggling to keep pace with rapidly evolving consumer attention patterns. The digital landscape is becoming more complex, with new platforms and purchasing mechanisms frequently emerging. “Attention spans are getting shorter and more fragmented,” warned Brandon Bobart, founder of Pisgah Peaks Ventures. “People are into social shopping via TikTok Shop. OpenAI just announced Etsy and Shopify one-click purchase ability in their chat search results, which further complicates things.” For brands operating under advertising restrictions, this fragmentation presents both challenges and opportunities. Earned media, influencer partnerships, and content marketing become even more critical when you can’t simply buy your way into consumer consciousness through traditional advertising channels. Usage patterns reveal long-term market growth Normalization is reflected in consumption frequency: Daily or near-daily use has increased sevenfold since 2000, reaching 17.7 million Americans according to a Carnegie Mellon University study. Among new users, half consume five or more days per week — a rate far higher than comparable alcohol data indicates. This isn’t just about getting high more often. Thirty-nine percent of consumers share cannabis with friends and family during holidays, integrating the plant into social rituals previously dominated by alcohol. Legalization has embedded cannabis into daily routines, creating opportunities for brands that can nurture product loyalty through automated reorder flows and subscription models. What this means for your strategy Taken together, these trends paint a clear picture: The 2026 cannabis consumer has leveled up — fast. The brands that thrive next year won’t be the ones making incremental tweaks. They’ll be the ones willing to rethink their approach from the ground up. *Here’s how to align your strategy with what buyers actually expect.* *What operators must do for 2026* Lead with wellness positioning and functional benefits Recreation and potency are no longer the best hooks. Educational, science-backed marketing that helps consumers achieve specific outcomes — better sleep, reduced anxiety, enhanced focus — will resonate far more than generic “premium quality” messaging. Invest in personalization and data infrastructure The 45 percent of consumers who say they’d shop more with personalized recommendations aren’t asking for much, but delivering on that expectation requires integrated data systems that connect online behavior, purchase history, and in-store interactions. Build authentic, founder-forward brand identities Communicate values and create genuine connections. In a commoditized market, story and purpose differentiate as much as product quality. Optimize for digital-first discovery and shopping Discovery starts online, even when final transactions happen in physical locations. An online presence isn’t marketing anymore. It’s the primary research and consideration phase of the customer journey. Meet consumers where their attention actually is Think micro-influencer partnerships, social commerce platforms, experiential activations, and earned media that builds credibility without triggering advertising restrictions. The cannabis industry’s adolescence is over. The brands that thrive in this mature market will be those that understand their consumers as complex, informed wellness seekers rather than one-dimensional stoners and build every aspect of their marketing and PR strategies accordingly. ------------------------------ The 2026 Marketing Cheat Sheet *Quick, data-backed answers to the biggest strategy questions operators are asking heading into 2026.* 1. What are the biggest cannabis marketing trends for 2026? The largest shifts include wellness-driven purchasing, the rise of discreet formats, science-backed product education, digital-first shopping, personalization, and a growing preference for founder-led brands. These trends reflect a more informed, mainstream consumer. 2. How is the 2026 cannabis consumer different? Consumers are older, more wellness-focused, more female, and significantly more digitally savvy. They expect transparency, tailored recommendations, simple workflows, and educational content that guides product choice. 3. What marketing strategies should cannabis brands prioritize in 2026? Brands should invest in personalization, build strong data infrastructure, embrace science-forward messaging, optimize digital shopping experiences, and strengthen founder-led storytelling. Earned media and experiential events also matter more than ever. 4. Which product categories will see fastest growth in 2026? Edibles, infused beverages, and pre-rolls continue to outpace traditional flower. Beverages in particular are showing rapid growth as mainstream retailers begin experimenting with THC product placement. 5. Why is personalization critical for cannabis marketing in 2026? More than half of consumers say they expect tailored recommendations, yet few brands deliver. Personalization removes choice paralysis, improves loyalty, and directly reduces customer churn. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

A GOP senator says it’s time to create a regulatory framework for marijuana with a federal excise tax and allow states to “opt in” to legalization—stating that he’s “not an anti-cannabis person” but stressing that certain rules should be implemented. < Back GOP Senator Wants To Let States ‘Opt In’ To Marijuana Legalization And Set A Federal Tax On It, Saying He’s ‘Not An Anti-Cannabis Person’ Oct 10, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A GOP senator says it’s time to create a regulatory framework for marijuana with a federal excise tax and allow states to “opt in” to legalization—stating that he’s “not an anti-cannabis person” but stressing that certain rules should be implemented. Sen. Thom Tillis (R-NC) might not be the voice most would expect to back comprehensive federal marijuana reform, but he’s been ringing the bell for months as he makes the case for regulation over prohibition. Part of his position is informed by concerns he has with a North Carolina-based tribe that legalized cannabis and markets the product despite the fact that the state itself has not yet moved forward with marijuana reform. In an interview with McClatchy that was published on Thursday, Tillis said, “We need to get rid of flavorings, eliminate Chinese imports, let states opt in, if they choose, and have rules of the road with excise tax and everything else.” Discussing the Eastern Band of Cherokee Indians (EBCI) that legalized marijuana within its territory in North Carolina, the senator said he’s displeased with the marketing approach that’s extended beyond the tribe’s borders. “I mean, gosh, when you’re doing the ads in Charlotte: ‘One of the country’s biggest dispensaries,’ and you’ve got a really cute app and you’re advertising all these fruity names and everything, and you’re an island—I mean unless you’re going there and having one hell of a weekend, we all know that people are taking it and bringing it back,” he said. “People need to know the minute they leave the boundary, they’re breaking the law.” “There are people lined up, the traffic is stopped. It’s amazing,” Tillis said, referencing the tribe’s dispensary. “I’m not an anti-cannabis person, but you’ve got to do it legally.” Michell Hicks, principal chief of EBCI, pushed back, saying that the tribe “operates squarely within the law” and saying that the senator “has chosen to ignore that truth to advance his own political agenda.” “Our operations are fully compliant with federal and tribal law, guided by safety, transparency, and accountability,” Hicks said. “Senator Tillis’ attacks are not about legality; they are about ego. To suggest the EBCI would endanger children through marketing or sales practices is inaccurate and it is offensive to the values that guide our tribe.” Tillis, for his part, also raised similar concerns about the tribe’s cannabis operation during a Senate Judiciary Committee hearing with Attorney General Pam Bondi on Tuesday. He said he has “no problem with” the legalization of sales in that territory generally—but that he still finds “concerning” with respect to the conflict between state and federal marijuana laws. “Nearly three dozen states [have] either medical, recreational or hybrid” cannabis models, the senator said. “But this kind of feels like to me, the way the tobacco industry got attacked for advertising to young people.” “This is just this worries me, because it’s a money-making enterprise. It kind of seems like it’s preying on younger people,” he said, pointing to an app that he claims allows people in states that prohibit cannabis to order marijuana products in a legal jurisdiction and then pick it up after crossing state boundaries. Tillis also said last month that the federal government needs to “step up” and explore a regulatory framework for marijuana—and that should include a pathway to explore the “efficacy” of cannabis for certain health conditions. At a separate Judiciary Committee hearing in June, Tillis said opponents of marijuana legalization “have lost” the fight to maintain prohibition and that “it’s time” for lawmakers to address that reality by creating a regulatory framework treating cannabis “in the same way that we do with alcohol and tobacco,” so that states can set their own policies without federal intervention. Back in February, the senator also raised the issue during a Senate Banking Committee hearing, saying “we should reexamine [federal marijuana laws].” But at the same time, “we damn sure shouldn’t do it by passing” legislation that would simply prevent federal regulators from penalizing banks that work with state-legal cannabis businesses. Tillis also said last December that he’s hopeful Congress will have a “discussion” about potentially creating a federal regulatory framework for marijuana in 2025, though he added that he personally wouldn’t vote to federally legalize cannabis. Last year, the senator also said he supports creating a “comprehensive regulatory framework that treats marijuana just like tobacco,” arguing that “the federal government needs to figure out a safe way to allow this market to occur.” Tillis in April joined Sen. Ted Budd (R-NC) in asking federal, state and local officials what steps they were taking to enforce marijuana prohibition as an Indian tribe prepared to launch recreational cannabis sales on its lands within North Carolina. Separately, Trump’s nominee for White House drug czar, Sara Carter, told members of the Judiciary Committee at a hearing last month that the administration is keeping “all options” on the table as it continues to consider the marijuana rescheduling proposal, while describing cannabis reform as a “bipartisan issue.” The committee advanced the nominee’s confirmation to the floor on Thursday. The post GOP Senator Wants To Let States ‘Opt In’ To Marijuana Legalization And Set A Federal Tax On It, Saying He’s ‘Not An Anti-Cannabis Person’ appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The US's 50% tariff on imports from India has impacted the cannabis industry's pre-roll category, which is its fastest-growing segment. This information was posted by MJBizDaily. < Back President Trump’s India tariffs threaten cannabis industry’s fastest-growing segment Sep 22, 2025 Margaret Jackson MJbizDaily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The cannabis industry’s fastest-growing product category — pre-rolls — hit a supply chain snag when the U.S. imposed a 50% tariff on imports from India. President Trump’s India tariffs threaten cannabis industry’s fastest-growing segment is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Multi-state cannabis operator Vireo Growth Inc. is acquiring Eaze Inc. for $47 million to enter the California and Florida markets, expanding its total footprint to 10 states with 166 dispensaries. The purchase includes Eaze's retail and delivery operations, and vertically integrated facilities, despite Eaze having filed for bankruptcy in 2024. < Back Vireo Growth Buys Eaze for $47M, Acquiring Assets In California, Florida, and Colorado Dec 29, 2025 Graham Abbott Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The multi-state cannabis operator Vireo Growth Inc. is set to enter the California and Florida cannabis markets with a $47 million acquisition of Eaze Inc. With the purchase, Vireo will absorb Eaze’s California-based retail and delivery operations, and its vertically integrated facilities in Florida. The acquisition also includes Eaze’s 14 dispensaries in Colorado, which will increase Vireo’s footprint there to 55 retailers. The acquisition expands Vireo’s operating footprint to 10 states with a total of 166 dispensaries, the company announced in a press release. “We are excited to announce the acquisition of Eaze and Vireo’s entrance into California and Florida. The addition of Eaze provides immediate scale in two of the country’s largest cannabis markets, and strengthens our position in Colorado.” — Vireo CEO John Mazarakis, in a statement Eaze CEO Cory Azzalino said, “Joining Vireo marks an exciting next chapter for Eaze,” and that the companies together are “well positioned to elevate retail and delivery experiences for customers across each market we serve.” Eaze, formerly known as Eaze Technologies Inc., was once valued at more than $700 million but filed for bankruptcy in 2024 after defaulting on a loan. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

RISE Joppa WEBSITE MENU REVIEWS 702 Pulaski Hwy, Joppatowne, MD, USA About OVERALL 4.1 average rating is 4.1 out of 5 EXPERIENCE 4.0 average rating is 4 out of 5 QUALITY 4.1 average rating is 4.1 out of 5 SERVICE 4.2 average rating is 4.2 out of 5 SELECTION 4.3 average rating is 4.3 out of 5 PRICES 3.8 average rating is 3.8 out of 5 RISE Joppa offers adult-use recreational and medical cannabis, featuring flower, pre-rolls, vapes, and edibles from brands like RYTHM and incredibles. Open daily from 9 AM to 9 PM, its Joppa space supports online ordering for pickup or delivery in Harford County. The dispensary’s menu includes daily deals like “Tasty Tuesdays” with 20% off edibles, appealing to Eastern Shore shoppers. Its sleek interior and expert staff ensure a polished experience. This RISE spot excels with its contemporary vibe and consistent offerings. Ascend Cannabis Recent Reviews Check back soon Once posts are published, you’ll see them here. Trending Nearby Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... PanLato - Curaleaf Dispensary (Columbia, Maryland) We were very curious about this Pan Lato that dropped recently at Curaleaf in Columbia, Maryland. It's a delectable dessert-like hybrid... Bubba Fett - RISE Dispensary (Bethesda, Maryland) We recently had the opportunity to try this Bubba Fett from Maryland marijuana dispensary, RISE Bethesda. As a fan of both Star Wars and... 1 2 3 4 5 best weed in DC (1,159) 1,159 posts DC flower (1,084) 1,084 posts DC I-71 (1,029) 1,029 posts terps (996) 996 posts DC Storefront (670) 670 posts heavy trichomes (660) 660 posts Indica Heavy Hybrid (611) 611 posts DC weed delivery (534) 534 posts starry trichomes (509) 509 posts Indica (475) 475 posts 50/50 Hybrid (421) 421 posts Sativa Dominant Hybrid (252) 252 posts Sativa (211) 211 posts Gelato (154) 154 posts DC Medical Marijuana (146) 146 posts Medical Marijuana (138) 138 posts Maryland Medical Marijuana (112) 112 posts Maryland Flower (104) 104 posts Runtz (101) 101 posts Elevated Lounge (95) 95 posts GSC (91) 91 posts alternative solutions (84) 84 posts Takoma Wellness Center (80) 80 posts The Gift Givers (78) 78 posts Maryland Recreational (75) 75 posts concentrate (74) 74 posts best weed in Maryland (74) 74 posts edibles (69) 69 posts Zkittles (69) 69 posts Alt Sol (59) 59 posts